Click here to get full coverage on Trading Systems Reacting to (KROS) Volatility - Stock Traders Daily

Trading Systems Reacting to (KROS) Volatility  Stock Traders Daily

Trading Systems Reacting to (KROS) Volatility - Stock Traders Daily

Click here to get full coverage on KROS Turns to Next Wave of TGF-Beta Muscle Therapies - Yahoo Finance

KROS Turns to Next Wave of TGF-Beta Muscle Therapies  Yahoo Finance

KROS Turns to Next Wave of TGF-Beta Muscle Therapies - Yahoo Finance

Click here to get full coverage on Kros Sivley Embraces Final Chapter at Southern Miss as Major Career Milestone Nears - Sports Illustrated

Kros Sivley Embraces Final Chapter at Southern Miss as Major Career Milestone Nears  Sports Illustrated

Kros Sivley Embraces Final Chapter at Southern Miss as Major Career Milestone Nears - Sports Illustrated

Click here to get full coverage on KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

KROS Financials: Income Statement, Balance Sheet & Cash Flow  Stock Titan

KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Click here to get full coverage on $KROS stock is down 12% today. Here's what we see in our data. - Quiver Quantitative

$KROS stock is down 12% today. Here's what we see in our data.  Quiver Quantitative

$KROS stock is down 12% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Ask the Pros: How Kros Strain Dialed in Its Flagship Hazy IPA, Fairy Nectar - Craft Beer & Brewing

Ask the Pros: How Kros Strain Dialed in Its Flagship Hazy IPA, Fairy Nectar  Craft Beer & Brewing

Ask the Pros: How Kros Strain Dialed in Its Flagship Hazy IPA, Fairy Nectar - Craft Beer & Brewing

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates - MSN

Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates  MSN

Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates - MSN

Click here to get full coverage on Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16 - Moomoo

Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16  Moomoo

Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16 - Moomoo

Click here to get full coverage on Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - Yahoo Finance Singapore

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?  Yahoo Finance Singapore

Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - Yahoo Finance Singapore

Click here to get full coverage on Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan - Stock Titan

Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan  Stock Titan

Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan - Stock Titan

Click here to get full coverage on Takeda to advance Keros anemia drug to Phase 3 as Q1 swings to $23.7M loss - Stock Titan

Takeda to advance Keros anemia drug to Phase 3 as Q1 swings to $23.7M loss  Stock Titan

Takeda to advance Keros anemia drug to Phase 3 as Q1 swings to $23.7M loss - Stock Titan

Click here to get full coverage on KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 - Yahoo Finance UK

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026  Yahoo Finance UK

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 - Yahoo Finance UK

Click here to get full coverage on Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan

Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS)  Stock Titan

Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates  Yahoo Finance

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Keros (NASDAQ: KROS) swings to Q1 2026 loss as Takeda license boost fades - Stock Titan

Keros (NASDAQ: KROS) swings to Q1 2026 loss as Takeda license boost fades  Stock Titan

Keros (NASDAQ: KROS) swings to Q1 2026 loss as Takeda license boost fades - Stock Titan

Click here to get full coverage on Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 - Yahoo Finance

Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20  Yahoo Finance

Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 - Yahoo Finance

Click here to get full coverage on KROS Stock: What to Know About Rinvatercept in DMD - Yahoo Finance

KROS Stock: What to Know About Rinvatercept in DMD  Yahoo Finance

KROS Stock: What to Know About Rinvatercept in DMD - Yahoo Finance

Click here to get full coverage on Keros Therapeutics (KROS) Revenue Collapse To US$0.4 Million Challenges Bullish Growth Narratives - simplywall.st

Keros Therapeutics (KROS) Revenue Collapse To US$0.4 Million Challenges Bullish Growth Narratives  simplywall.st

Keros Therapeutics (KROS) Revenue Collapse To US$0.4 Million Challenges Bullish Growth Narratives - simplywall.st

Click here to get full coverage on Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - Yahoo Finance

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?  Yahoo Finance

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - Yahoo Finance

Click here to get full coverage on Keros Therapeutics (KROS) swings to Q1 2026 loss as Takeda revenue steps down - Stock Titan

Keros Therapeutics (KROS) swings to Q1 2026 loss as Takeda revenue steps down  Stock Titan

Keros Therapeutics (KROS) swings to Q1 2026 loss as Takeda revenue steps down - Stock Titan

Click here to get full coverage on How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN

How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%  MSN

How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN

Click here to get full coverage on KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Yahoo Finance

KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?  Yahoo Finance

KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Yahoo Finance

Click here to get full coverage on KROS: Is the Discount Book Value a Value Trap? - Yahoo Finance

KROS: Is the Discount Book Value a Value Trap?  Yahoo Finance

KROS: Is the Discount Book Value a Value Trap? - Yahoo Finance

Click here to get full coverage on Biotech behind new DMD and ALS trials turns 2024 loss into 2025 profit - Stock Titan

Biotech behind new DMD and ALS trials turns 2024 loss into 2025 profit  Stock Titan

Biotech behind new DMD and ALS trials turns 2024 loss into 2025 profit - Stock Titan

Click here to get full coverage on KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026 - Yahoo Finance

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026  Yahoo Finance

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026 - Yahoo Finance

Click here to get full coverage on Ex-Lyell CFO and healthcare banker Charles Newton joins Keros board - Stock Titan

Ex-Lyell CFO and healthcare banker Charles Newton joins Keros board  Stock Titan

Ex-Lyell CFO and healthcare banker Charles Newton joins Keros board - Stock Titan

Click here to get full coverage on Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why - Yahoo Finance

Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why  Yahoo Finance

Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why - Yahoo Finance

Click here to get full coverage on KROS Rinvatercept: What to Know Before DMD Phase II Starts - Yahoo Finance

KROS Rinvatercept: What to Know Before DMD Phase II Starts  Yahoo Finance

KROS Rinvatercept: What to Know Before DMD Phase II Starts - Yahoo Finance

Click here to get full coverage on Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year - The Globe and Mail

Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year  The Globe and Mail

Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year - The Globe and Mail

Click here to get full coverage on Is Keros Therapeutics Stock Built to Withstand More Downside? - Trefis

Is Keros Therapeutics Stock Built to Withstand More Downside?  Trefis

Is Keros Therapeutics Stock Built to Withstand More Downside? - Trefis

Click here to get full coverage on Jason Kros - Men's Tennis Coach - Ole Miss Athletics - Hotty Toddy - Ole Miss Athletics

Jason Kros - Men's Tennis Coach - Ole Miss Athletics - Hotty Toddy  Ole Miss Athletics

Jason Kros - Men's Tennis Coach - Ole Miss Athletics - Hotty Toddy - Ole Miss Athletics

Click here to get full coverage on Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%  simplywall.st

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st

Click here to get full coverage on Royce Sheibal Obituary - Papillion, NE - Dignity Memorial

Royce Sheibal Obituary - Papillion, NE  Dignity Memorial

Royce Sheibal Obituary - Papillion, NE - Dignity Memorial

Click here to get full coverage on Andrew Kros EA SPORTS™ College Football 26 Player Ratings - National Championship - Electronic Arts Home Page

Andrew Kros EA SPORTS™ College Football 26 Player Ratings - National Championship  Electronic Arts Home Page

Andrew Kros EA SPORTS™ College Football 26 Player Ratings - National Championship - Electronic Arts Home Page

Click here to get full coverage on KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - TradingView

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?  TradingView

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - TradingView

Click here to get full coverage on Keros Therapeutics (KROS) awards 80,000 stock options to Chief Legal Officer - Stock Titan

Keros Therapeutics (KROS) awards 80,000 stock options to Chief Legal Officer  Stock Titan

Keros Therapeutics (KROS) awards 80,000 stock options to Chief Legal Officer - Stock Titan

Click here to get full coverage on Veteran Sivley bringing experience, leadership to 2026 USM pitching staff - WDAM-TV

Veteran Sivley bringing experience, leadership to 2026 USM pitching staff  WDAM-TV

Veteran Sivley bringing experience, leadership to 2026 USM pitching staff - WDAM-TV

Click here to get full coverage on KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - TradingView

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment  TradingView

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - TradingView

Click here to get full coverage on Keros Therapeutics (KROS): Valuation Check After Sharp Share Price Rebound and Ongoing Revenue Contraction Forecasts - simplywall.st

Keros Therapeutics (KROS): Valuation Check After Sharp Share Price Rebound and Ongoing Revenue Contraction Forecasts  simplywall.st

Keros Therapeutics (KROS): Valuation Check After Sharp Share Price Rebound and Ongoing Revenue Contraction Forecasts - simplywall.st

Click here to get full coverage on Men’s Tennis Adds Jason Kros as Assistant Coach - Ole Miss Athletics

Men’s Tennis Adds Jason Kros as Assistant Coach  Ole Miss Athletics

Men’s Tennis Adds Jason Kros as Assistant Coach - Ole Miss Athletics

Click here to get full coverage on Personalized ALS trial to test Keros rinvatercept at Mass General - Stock Titan

Personalized ALS trial to test Keros rinvatercept at Mass General  Stock Titan

Personalized ALS trial to test Keros rinvatercept at Mass General - Stock Titan

Click here to get full coverage on Keros Therapeutics 4Q Rev $385,000 >KROS - Moomoo

Keros Therapeutics 4Q Rev $385,000 >KROS  Moomoo

Keros Therapeutics 4Q Rev $385,000 >KROS - Moomoo

Click here to get full coverage on Responsive Playbooks and the KROS Inflection - Stock Traders Daily

Responsive Playbooks and the KROS Inflection  Stock Traders Daily

Responsive Playbooks and the KROS Inflection - Stock Traders Daily

Click here to get full coverage on Keros Therapeutics (NASDAQ: KROS) lands $200M Takeda deal and advances DMD, ALS programs - Stock Titan

Keros Therapeutics (NASDAQ: KROS) lands $200M Takeda deal and advances DMD, ALS programs  Stock Titan

Keros Therapeutics (NASDAQ: KROS) lands $200M Takeda deal and advances DMD, ALS programs - Stock Titan

Click here to get full coverage on Jason Kros - Ole Miss Athletics

Jason Kros - Ole Miss Athletics

Click here to get full coverage on 'A beer for everybody': Beer brewed in La Vista named official craft beer of the Huskers - KETV

'A beer for everybody': Beer brewed in La Vista named official craft beer of the Huskers  KETV

'A beer for everybody': Beer brewed in La Vista named official craft beer of the Huskers - KETV

Click here to get full coverage on PHOTOS: KROS hosts 'Voice of the Hawkkeyes' Gary Dolphin - Clinton Herald

PHOTOS: KROS hosts 'Voice of the Hawkkeyes' Gary Dolphin  Clinton Herald

PHOTOS: KROS hosts 'Voice of the Hawkkeyes' Gary Dolphin - Clinton Herald

Click here to get full coverage on Lois (Kros) Hurley Obituary | Hillside Funeral Home & Cremation Center | Highland, IN - Tribute Archive

Lois (Kros) Hurley Obituary | Hillside Funeral Home & Cremation Center | Highland, IN  Tribute Archive

Lois (Kros) Hurley Obituary | Hillside Funeral Home & Cremation Center | Highland, IN - Tribute Archive

Click here to get full coverage on Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? - The Globe and Mail

Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?  The Globe and Mail

Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? - The Globe and Mail

Click here to get full coverage on Husker fans can cheer with beer: ‘Cornhusker Crusher’ debuts alongside custom Bud Light can - KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

Husker fans can cheer with beer: ‘Cornhusker Crusher’ debuts alongside custom Bud Light can  KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

Husker fans can cheer with beer: ‘Cornhusker Crusher’ debuts alongside custom Bud Light can - KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

Click here to get full coverage on Ukrainian veteran Kristina Sanina walks runway at Fashion Week - The New Voice of Ukraine

Ukrainian veteran Kristina Sanina walks runway at Fashion Week  The New Voice of Ukraine

Ukrainian veteran Kristina Sanina walks runway at Fashion Week - The New Voice of Ukraine

Click here to get full coverage on Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan

Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event  Stock Titan

Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan

Click here to get full coverage on Jason Kros - Men's Tennis Coach - Princeton University Athletics

Jason Kros - Men's Tennis Coach  Princeton University Athletics

Jason Kros - Men's Tennis Coach - Princeton University Athletics

Click here to get full coverage on Lily Aragon on leading fast-growing DOD and aero specialist Kros-Wise - Runway Girl

Lily Aragon on leading fast-growing DOD and aero specialist Kros-Wise  Runway Girl

Lily Aragon on leading fast-growing DOD and aero specialist Kros-Wise - Runway Girl

Click here to get full coverage on Is Keros Therapeutics (KROS) Stock Breaking Out | Price at $11.60, Down 7.13% - Retail Flow - Xã Thanh Hà

Is Keros Therapeutics (KROS) Stock Breaking Out | Price at $11.60, Down 7.13% - Retail Flow  Xã Thanh Hà

Is Keros Therapeutics (KROS) Stock Breaking Out | Price at $11.60, Down 7.13% - Retail Flow - Xã Thanh Hà

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Class of 2021: Ryan Kros looks ahead to careers in the Army and residential construction - Virginia Tech News

Class of 2021: Ryan Kros looks ahead to careers in the Army and residential construction  Virginia Tech News

Class of 2021: Ryan Kros looks ahead to careers in the Army and residential construction - Virginia Tech News

Click here to get full coverage on Is Keros Therapeutics (KROS) Stock Breaking Out | Price at $11.60, Down 7.13% - Portfolio Management - Cổng thông tin điện tử tỉnh Lào Cai

Is Keros Therapeutics (KROS) Stock Breaking Out | Price at $11.60, Down 7.13% - Portfolio Management  Cổng thông tin điện tử tỉnh Lào Cai

Is Keros Therapeutics (KROS) Stock Breaking Out | Price at $11.60, Down 7.13% - Portfolio Management - Cổng thông tin điện tử tỉnh Lào Cai

Click here to get full coverage on This Weekly Event Drives Kros Strain Consumers to its Taproom on Fridays - The Brewer Magazine

This Weekly Event Drives Kros Strain Consumers to its Taproom on Fridays  The Brewer Magazine

This Weekly Event Drives Kros Strain Consumers to its Taproom on Fridays - The Brewer Magazine

Click here to get full coverage on “Time Out” with Southern Miss pitcher Kros Sivley - WDAM-TV

“Time Out” with Southern Miss pitcher Kros Sivley  WDAM-TV

“Time Out” with Southern Miss pitcher Kros Sivley - WDAM-TV

Click here to get full coverage on Kros Jones' High School Career Home - MaxPreps

Kros Jones' High School Career Home  MaxPreps

Kros Jones' High School Career Home - MaxPreps

Click here to get full coverage on Sumrall’s Kros Sivley stepping up for Southern Miss - WDAM-TV

Sumrall’s Kros Sivley stepping up for Southern Miss  WDAM-TV

Sumrall’s Kros Sivley stepping up for Southern Miss - WDAM-TV

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - Yahoo Finance

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial  Yahoo Finance

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - Yahoo Finance

Click here to get full coverage on Cornelia Kros Obituary (1934 - 2025) - Millcreek, UT - Deseret News - Legacy obituary

Cornelia Kros Obituary (1934 - 2025) - Millcreek, UT - Deseret News  Legacy obituary

Cornelia Kros Obituary (1934 - 2025) - Millcreek, UT - Deseret News - Legacy obituary

Click here to get full coverage on Thomas J. Kros Jr. Obituary - Green Bay Press-Gazette

Thomas J. Kros Jr. Obituary  Green Bay Press-Gazette

Thomas J. Kros Jr. Obituary - Green Bay Press-Gazette

Click here to get full coverage on Edward Kros Obituary (1942 - 2024) - Omaha, NE - Omaha World-Herald - Legacy obituary

Edward Kros Obituary (1942 - 2024) - Omaha, NE - Omaha World-Herald  Legacy obituary

Edward Kros Obituary (1942 - 2024) - Omaha, NE - Omaha World-Herald - Legacy obituary

Click here to get full coverage on Edgar "Kros" G. Lucero Obituary October 4, 2024 - Sunset Funeral Homes - El Paso, TX

Edgar "Kros" G. Lucero Obituary October 4, 2024  Sunset Funeral Homes - El Paso, TX

Edgar "Kros" G. Lucero Obituary October 4, 2024 - Sunset Funeral Homes - El Paso, TX

Click here to get full coverage on KROS radio in Clinton, Iowa has signal picked up in the Arctic Circle - WQAD

KROS radio in Clinton, Iowa has signal picked up in the Arctic Circle  WQAD

KROS

Price Chart

Key Statistics

Technicals

About KROS

Latest News

Trading Systems Reacting to (KROS) Volatility - Stock Traders Daily

KROS Turns to Next Wave of TGF-Beta Muscle Therapies - Yahoo Finance

Kros Sivley Embraces Final Chapter at Southern Miss as Major Career Milestone Nears - Sports Illustrated

Advanced Charts

Top Gainers

Top Losers